Fortesta
PreclinicalSmall molecule
Endo PharmaceuticalsFortesta is one of 34 small molecule programs targeting Hypogonadism. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Hypogonadism
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Estrace
Novo NordiskApproved
Andriol
AAuxilium
Approved
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Trelstar
OOncoVerity, Inc.
Approved
Arimidex
IIstituto Clinico Humanitas
Approved
Delatestryl
AAntares Pharma Inc.
Approved
Avodart
Akero TherapeuticsApproved
Clomid
EMD SeronoApproved
Human Chorionic Gonadotropin
Merck & Co.Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fortesta. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company